[Bepridil--electrophysiologic properties of a new calcium antagonist with an anti-arrhythmia effect].
In 12 patients with recurrent pre-syncope or syncope and suspected sick sinus syndrome, the electrophysiologic properties of bepridil were tested using 1-2 extrastimuli during four basic pacing rates. Bepridil was given in a dose of 5 mg/kg body weight over 10 min. It caused no significant changes in sinus cycle length (+5%) and corrected sinus node recovery time during pacing of 100/min (-6%), 120/min (+8%) and 140/min (+4%). The conduction times PQ- (+10%) and QRS-interval (+6%) increased significantly, AH- (+8%) and HV-interval (+5%) were slightly prolonged. Antegrade Wenckebach point increased from 460 to 508 ms (p less than 0.05). The effective refractory period was prolonged in the atrium (+11%, p less than 0.05), the AV-node (+14%, p less than 0.05) and the right ventricle (6-11% at pacing rates 100-140/min, p less than 0.05 for each cycle length). In relation to the pacing rate, QTc-interval increased highly significantly (p less than 0.01) by 16% (sinus rhythm), 12% (100/min), 20% (120/min) and 19% (140/min). After a mean of 5 min after the start of infusion a doubled T-wave was observed in 11/12 patients, persisting during Holter monitoring for several hours without evidence of increased incidence of spontaneous ventricular arrhythmias. During programmed electrical stimulation with 1-2 extrastimuli, no increase in vulnerability of the right ventricle was obvious in any patient.
Zehender
M
M
Innere Medizin III, Universitätsklinik Freiburg.
Geibel
A
A
Henning
B
B
Hohnloser
S
S
Meinertz
T
T
Just
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D015764:Bepridil; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002304:Cardiac Pacing, Artificial; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011759:Pyrrolidines / Q000627:therapeutic use*; D012804:Sick Sinus Syndrome / Q000188:drug therapy; D012849:Sinoatrial Node / Q000187:drug effects; D013575:Syncope / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D011759:Pyrrolidines; D015764:Bepridil
Bepridil--Elektrophysiologische Eigenschaften eines neuen Kalziumantagonisten mit antiarrhythmischer Wirksamkeit.